Copyright
©The Author(s) 2020.
World J Hepatol. May 27, 2020; 12(5): 184-206
Published online May 27, 2020. doi: 10.4254/wjh.v12.i5.184
Published online May 27, 2020. doi: 10.4254/wjh.v12.i5.184
Figure 6 BPC 157 counteracts ascites (mL) (upper), increased MDA-level (nmol/mg protein) in liver (low), in ischemia and reperfusion, and thrombus presentation (thrombus mass, g) in veins [inferior caval vein, portal vein, superior mesenteric vein, lienal vein] and artery (hepatic artery) (middle) during portal triad obstruction.
Assessment at 30 min portal triad obstruction (PTO)-ligation time, and in reperfusion, at 15 min and 24 h reperfusion time, mean ± SD. At 1 min post-injury (PTO-ligation time) (ischemia), or at 1 min reperfusion-time (post-PTO-ligation time) (reperfusion), medication (BPC 157, 10 μg/kg, 10 ng/kg, saline 5 mL/kg (1 mL/rat)) as a bath. aP < 0.05 vs saline. aP < 0.05, at least vs healthy liver.
- Citation: Kolovrat M, Gojkovic S, Krezic I, Malekinusic D, Vrdoljak B, Kasnik Kovac K, Kralj T, Drmic D, Barisic I, Horvat Pavlov K, Petrovic A, Duzel A, Knezevic M, Mirkovic I, Kokot A, Boban Blagaic A, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion. World J Hepatol 2020; 12(5): 184-206
- URL: https://www.wjgnet.com/1948-5182/full/v12/i5/184.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i5.184